Tenax Therapeutics, Inc.

Clinical trials sponsored by Tenax Therapeutics, Inc., explained in plain language.

Tenax Therapeutics, Inc. TENX NASDAQ

A specialty pharmaceutical company developing treatments for cardiovascular and pulmonary diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 2 Completed 1 Terminated 1

Heart failure drug levosimendan tested for long-term safety in 35 patients

Disease control Completed

This study looked at the safety of using levosimendan over a longer period in people who have both pulmonary hypertension and heart failure with preserved ejection fraction. 35 patients who had already been in a related study received the drug and were monitored for side effects.…

Phase 2 • Sponsor: Tenax Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

Tenax Therapeutics, Inc.

Heart failure drug levosimendan tested for long-term safety in 35 patients